Abstract
BackgroundSecukinumab (SEC), a fully human monoclonal antibody (mAb) that selectively targets IL-17A, is highly efficacious for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS). mAb therapies may be...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have